|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FERMT2 |
Gene summary for FERMT2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FERMT2 | Gene ID | 10979 |
| Gene name | FERM domain containing kindlin 2 | |
| Gene Alias | KIND2 | |
| Cytomap | 14q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q96AC1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10979 | FERMT2 | P2T-E | Human | Esophagus | ESCC | 1.02e-09 | 1.63e-01 | 0.1177 |
| 10979 | FERMT2 | P4T-E | Human | Esophagus | ESCC | 2.45e-06 | 4.69e-01 | 0.1323 |
| 10979 | FERMT2 | P5T-E | Human | Esophagus | ESCC | 7.03e-05 | 2.62e-01 | 0.1327 |
| 10979 | FERMT2 | P8T-E | Human | Esophagus | ESCC | 6.83e-14 | 2.37e-01 | 0.0889 |
| 10979 | FERMT2 | P9T-E | Human | Esophagus | ESCC | 2.10e-15 | 3.38e-01 | 0.1131 |
| 10979 | FERMT2 | P10T-E | Human | Esophagus | ESCC | 4.95e-21 | 4.56e-01 | 0.116 |
| 10979 | FERMT2 | P11T-E | Human | Esophagus | ESCC | 1.10e-04 | 3.85e-01 | 0.1426 |
| 10979 | FERMT2 | P12T-E | Human | Esophagus | ESCC | 8.68e-15 | 3.61e-01 | 0.1122 |
| 10979 | FERMT2 | P16T-E | Human | Esophagus | ESCC | 1.97e-12 | 2.96e-01 | 0.1153 |
| 10979 | FERMT2 | P19T-E | Human | Esophagus | ESCC | 1.52e-06 | 1.01e+00 | 0.1662 |
| 10979 | FERMT2 | P20T-E | Human | Esophagus | ESCC | 1.01e-02 | 4.70e-02 | 0.1124 |
| 10979 | FERMT2 | P21T-E | Human | Esophagus | ESCC | 4.15e-03 | 9.79e-02 | 0.1617 |
| 10979 | FERMT2 | P22T-E | Human | Esophagus | ESCC | 5.14e-03 | 1.09e-01 | 0.1236 |
| 10979 | FERMT2 | P23T-E | Human | Esophagus | ESCC | 3.81e-05 | 1.34e-01 | 0.108 |
| 10979 | FERMT2 | P24T-E | Human | Esophagus | ESCC | 4.09e-16 | 4.75e-01 | 0.1287 |
| 10979 | FERMT2 | P26T-E | Human | Esophagus | ESCC | 9.45e-09 | 3.55e-01 | 0.1276 |
| 10979 | FERMT2 | P28T-E | Human | Esophagus | ESCC | 5.50e-18 | 4.03e-01 | 0.1149 |
| 10979 | FERMT2 | P30T-E | Human | Esophagus | ESCC | 3.29e-11 | 4.68e-01 | 0.137 |
| 10979 | FERMT2 | P32T-E | Human | Esophagus | ESCC | 4.41e-06 | 3.78e-01 | 0.1666 |
| 10979 | FERMT2 | P36T-E | Human | Esophagus | ESCC | 5.49e-05 | 2.39e-01 | 0.1187 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190002420 | Esophagus | ESCC | regulation of substrate adhesion-dependent cell spreading | 38/8552 | 57/18723 | 1.11e-03 | 5.56e-03 | 38 |
| GO:003223120 | Esophagus | ESCC | regulation of actin filament bundle assembly | 64/8552 | 105/18723 | 1.15e-03 | 5.70e-03 | 64 |
| GO:003223319 | Esophagus | ESCC | positive regulation of actin filament bundle assembly | 41/8552 | 63/18723 | 1.48e-03 | 6.99e-03 | 41 |
| GO:005149225 | Esophagus | ESCC | regulation of stress fiber assembly | 56/8552 | 91/18723 | 1.66e-03 | 7.68e-03 | 56 |
| GO:003444620 | Esophagus | ESCC | substrate adhesion-dependent cell spreading | 65/8552 | 108/18723 | 1.67e-03 | 7.72e-03 | 65 |
| GO:00487367 | Esophagus | ESCC | appendage development | 98/8552 | 172/18723 | 1.83e-03 | 8.37e-03 | 98 |
| GO:00601737 | Esophagus | ESCC | limb development | 98/8552 | 172/18723 | 1.83e-03 | 8.37e-03 | 98 |
| GO:00456675 | Esophagus | ESCC | regulation of osteoblast differentiation | 77/8552 | 132/18723 | 2.28e-03 | 1.00e-02 | 77 |
| GO:190002620 | Esophagus | ESCC | positive regulation of substrate adhesion-dependent cell spreading | 28/8552 | 41/18723 | 2.88e-03 | 1.21e-02 | 28 |
| GO:00604856 | Esophagus | ESCC | mesenchyme development | 156/8552 | 291/18723 | 3.76e-03 | 1.53e-02 | 156 |
| GO:00456695 | Esophagus | ESCC | positive regulation of osteoblast differentiation | 43/8552 | 69/18723 | 3.93e-03 | 1.59e-02 | 43 |
| GO:01501178 | Esophagus | ESCC | positive regulation of cell-substrate junction organization | 23/8552 | 33/18723 | 4.57e-03 | 1.78e-02 | 23 |
| GO:003103219 | Esophagus | ESCC | actomyosin structure organization | 108/8552 | 196/18723 | 4.86e-03 | 1.88e-02 | 108 |
| GO:011002025 | Esophagus | ESCC | regulation of actomyosin structure organization | 59/8552 | 100/18723 | 4.98e-03 | 1.91e-02 | 59 |
| GO:00455984 | Esophagus | ESCC | regulation of fat cell differentiation | 79/8552 | 139/18723 | 5.23e-03 | 1.97e-02 | 79 |
| GO:004308715 | Esophagus | ESCC | regulation of GTPase activity | 183/8552 | 348/18723 | 5.34e-03 | 2.00e-02 | 183 |
| GO:190303420 | Esophagus | ESCC | regulation of response to wounding | 93/8552 | 167/18723 | 5.77e-03 | 2.14e-02 | 93 |
| GO:005149610 | Esophagus | ESCC | positive regulation of stress fiber assembly | 33/8552 | 52/18723 | 7.38e-03 | 2.65e-02 | 33 |
| GO:190303617 | Esophagus | ESCC | positive regulation of response to wounding | 43/8552 | 72/18723 | 1.14e-02 | 3.84e-02 | 43 |
| GO:009030310 | Esophagus | ESCC | positive regulation of wound healing | 36/8552 | 59/18723 | 1.27e-02 | 4.21e-02 | 36 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FERMT2 | SNV | Missense_Mutation | novel | c.1513N>T | p.Pro505Ser | p.P505S | Q96AC1 | protein_coding | tolerated(0.31) | benign(0.012) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FERMT2 | SNV | Missense_Mutation | c.1900N>C | p.Glu634Gln | p.E634Q | Q96AC1 | protein_coding | tolerated(0.64) | possibly_damaging(0.677) | TCGA-C8-A1HF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FERMT2 | insertion | Frame_Shift_Ins | novel | c.1909_1910insGGCTTAACCTATATGAACTCTATTTATCATGTCTA | p.Asp637GlyfsTer24 | p.D637Gfs*24 | Q96AC1 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| FERMT2 | deletion | Frame_Shift_Del | novel | c.55delN | p.Glu19AsnfsTer2 | p.E19Nfs*2 | Q96AC1 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| FERMT2 | SNV | Missense_Mutation | c.1095T>G | p.Ile365Met | p.I365M | Q96AC1 | protein_coding | tolerated(0.29) | possibly_damaging(0.653) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FERMT2 | SNV | Missense_Mutation | c.997N>C | p.Glu333Gln | p.E333Q | Q96AC1 | protein_coding | tolerated(0.5) | benign(0.291) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| FERMT2 | SNV | Missense_Mutation | c.720A>T | p.Gln240His | p.Q240H | Q96AC1 | protein_coding | deleterious(0.02) | possibly_damaging(0.871) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| FERMT2 | SNV | Missense_Mutation | c.1997N>A | p.Arg666His | p.R666H | Q96AC1 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3509-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FERMT2 | SNV | Missense_Mutation | c.1316T>G | p.Phe439Cys | p.F439C | Q96AC1 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-3851-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| FERMT2 | SNV | Missense_Mutation | c.106A>G | p.Thr36Ala | p.T36A | Q96AC1 | protein_coding | tolerated(0.35) | benign(0.108) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |